US Stock Insider Trading | Talphera disclosed 10 insider transactions on February 20

2026-02-21 19:50:20

On February 20, 2026, Talphera (TLPH) disclosed 10 insider trading transactions. Director Angotti Vincent J. purchased 105,400 shares on February 14, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 20, 2026	Executive	ASADORIAN RAFFI	February 14, 2026	Sell	2,933	0.79	2,327.04
February 20, 2026	Executive	ASADORIAN RAFFI	February 12, 2026	Buy	45,000	0.81	36,600
February 20, 2026	Executive	Dasu Badri N	February 10, 2026	Sell	781	0.84	652.99
February 20, 2026	Executive	Dasu Badri N	February 12, 2026	Buy	35,000	0.81	28,100
February 20, 2026	Director	Angotti Vincent J.	February 14, 2026	Sell	9,559	0.79	7,584.11
February 20, 2026	Executive	Dasu Badri N	February 14, 2026	Sell	2,346	0.79	1,861.32
February 20, 2026	Director	Angotti Vincent J.	February 12, 2026	Buy	105,400	0.81	85,600
February 20, 2026	Director	Angotti Vincent J.	February 10, 2026	Sell	3,179	0.84	2,657.96
February 20, 2026	Executive	Aslam Shakil	February 12, 2026	Buy	35,000	0.81	28,100
February 20, 2026	Executive	ASADORIAN RAFFI	February 10, 2026	Sell	958	0.84	800.98

【Company Information】

Talphera, Inc. was initially registered as SuRX, Inc. in Delaware on July 13, 2005. The company later renamed itself AcelRx Pharmaceuticals, and on January 10, 2024, it changed its name to Talphera, Inc. The company is a specialty pharmaceutical firm focused on developing and commercializing innovative therapies for use in regulated medical environments. Talphera’s lead candidate, Niyad, is a lyophilized formulation of nafamostat currently under investigation as an extracorporeal anticoagulant under an Investigational Device Exemption (IDE), and has received Breakthrough Device designation from the FDA. Talphera is also developing two prefilled syringes licensed from partner Aguettant: Fedsyra, a prefilled ephedrine syringe, and PFS-02, a prefilled norepinephrine syringe.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes